Mutations in KIT confer imatinib resistance in gastrointestinal stromal tumors
US7329495B2 · kind B2 · utility
8Cited by
11References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 9, 2005 |
| Grant date | Feb 12, 2008 |
| Priority date | — |
| Expiry date | Jun 9, 2025 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/106
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present invention relates to methods and compositions concerning resistance to a drug for cancer comprising aberrant KIT signal, such as aberrant KIT sequence or expression. In a specific embodiment, the cancer is also initially responsive to imatinib therapy, such as in gastrointestinal stromal tumors (GISTs). In particular embodiments, a mutation in a KIT polynucleotide confers resistance to imatinib treatment, and in specific embodiments the exemplary mutation is at 1982T→C. Thus, the invention provides a means to adjust for or circumvent the resistance to imatinib drug treatment.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.